Dyadic's c1 platform selected by the vaccine and immunotherapy center (“vic”) at massachusetts general hospital as part of vic's $5.88 million award by u.s. dod to develop a self-assembling vaccine (sav) platform for rapid production of prophylactic vaccines for infectious diseases
Jupiter, fla., oct. 05, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the vaccine and immunotherapy center (“vic”) at massachusetts general hospital, as part of vic's collaboration with voltron therapeutics, inc. (“voltron”), to use dyadic's proprietary c1 protein production platform to express vaccine antigens for influenza a and other infectious diseases.
DYAI Ratings Summary
DYAI Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission